There are a variety of device-based solutions under development for the treatment of heart failure (HF), and researchers and manufacturers are uncovering innovative ways to help slow, and potentially reverse, the course of this debilitating and deadly chronic disease. Companies active in this field face many formidable challenges; however, they also could reap huge rewards if they are able to offer a cost-effective therapy that improves outcomes for the large and fast-growing HF population, currently estimated at 23 million people worldwide. (Also see Also see "Heart Failure Start-Ups Balance High-Risk, High-Reward Opportunity" - Medtech Insight, 17 July, 2013..)
HF affects an estimated five million people in the US alone, and by 2030, that number could grow by nearly 50%, to eight million, as the population ages, according to...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?